Filing Details

Accession Number:
0001104659-21-101719
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-06 21:01:02
Reporting Period:
2021-08-04
Accepted Time:
2021-08-06 21:01:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1737953 Replimune Group Inc. REPL Biological Products, (No Disgnostic Substances) (2836) 822082553
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1744425 Pamela Esposito C/O Replimune Group, Inc.
500 Unicorn Park
Woburn MA 01801
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-08-04 4,200 $15.50 214,359 No 4 M Direct
Common Stock Disposition 2021-08-04 4,200 $35.00 210,159 No 4 S Direct
Common Stock Acquisiton 2021-08-05 25,800 $15.50 235,959 No 4 M Direct
Common Stock Disposition 2021-08-05 25,800 $35.09 210,159 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-08-04 4,200 $0.00 4,200 $15.50
Common Stock Employee Stock Option (right to buy) Disposition 2021-08-05 25,800 $0.00 25,800 $15.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
71,550 2029-04-01 No 4 M Direct
45,750 2029-04-01 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on December 14, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
  2. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35 to $35.05. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $35 to $35.38. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. Following the sales reported on this Form 4, the reporting person continues to beneficially own 210,159 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 458,102 shares of the Issuer's common stock, 300,811 of which are exercisable as of the date hereof.
  5. 25% of the shares underlying this stock option vested on April 1, 2020, and the remainder of the shares underlying this stock option vested or will vest, as applicable, in 36 approximately equal monthly installments thereafter.